Wecare Probiotics Co., Ltd., a leader in probiotic research and innovation, is thrilled to highlight a groundbreaking study that showcases the potential of probiotics in supporting post-menopausal women's health.

The science surrounding Akkermansia muciniphila is rapidly advancing, revealing its significant potential in supporting metabolic health, enhancing gut barrier function, and modulating inflammation.

This invention pertains to a probiotic composition designed to promote development and height increase, containing two strains: Bifidobacterium longum subsp. longum BL21 and Bifidobacterium breve BBr16.

This probiotic combination shows promise as a preventive and therapeutic agent for oral health, especially in mitigating pathogenic bacterial growth and reducing inflammation in periodontal disease.

Animal model experiments show that a mixture of LA85 and BLa80 can alleviate the inflammation caused by H. pylori infection. The combination of these strains proves more effective in relieving inflammation than either strain alone.

This probiotic patent focuses on a dual-strain formulation targeting osteoporosis improvement. The formulation contains Limosilactobacillus reuteri LR38 and Lacticaseibacillus rhamnosus LRa05, which together exhibit synergistic effects on bone health by mitigating bone density loss and decreasing osteoclastogenic factors.